Skip to main content
SpringerLink
Log in

Comparative Tolerability Profiles of the Newer versus Older Antidepressants

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Although the standard tricyclic antidepressants (TCAs) are generally effective in the treatment of depression, they can cause several troublesome adverse effects. Chief among these are their anticholinergic actions, which range from annoying dryness of the mouth and constipation to potentially dangerous urinary retention and confusion or delirium in the ill and elderly. Cardiovascular effects of TCAs include orthostatic hypotension, tachycardia and cardiac conduction slowing. Many TCAs are sedating and promote weight gain. Also problematic is the potential lethality of TCAs in overdose. The continual introduction of a host of new antidepressants over the past 15 years has provided an opportunity to improve the benefit-risk ratio for many patients by reducing medication-related toxicity. Selective serotonin reuptake inhibitors (SSRIs) and amfebutamone (bupropion), among others, are examples of effective antidepressants free of tricyclic-like anticholinergic, cardiovascular, sedating and appetite/weight-increasing effects. However, the new-generation drugs also present adverse effects of their own, including gastrointestinal distress, agitation and drug-drug interactions in the case of the SSRIs, and the risk of seizures or psychosis in amfebutamone recipients. Monoamine oxidase (MAO) inhibitors have also been refined; reversible inhibitors of MAO-type A afford protection against the usually feared hypertensive reaction to indirect sympathomimetic substances. The availability of new-generation antidepressants thus increases the likelihood of clinical response with a reduction in unwanted toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aizenberg D, Zemishlany Z, Hermesh H, Karp L, Weizman A. Painful ejaculation associated with antidepressants in four patients. Journal of Clinical Psychiatry 52: 461–463, 1991

    PubMed  CAS  Google Scholar 

  • Alevizos B, Hatzimanolis J, Markianos M, Stefanis CN. Clinical, endocrine and neurochemical effects of moclobemide in depressed patients. Acta Psychiatrica Scandinavica 87: 285–290, 1993

    PubMed  CAS  Google Scholar 

  • Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. International Journal of Clinical Pharmacology Research 10: 293–298, 1990

    PubMed  CAS  Google Scholar 

  • Amitai Y, Erickson T, Kennedy EJ, Leikin JB, Hryhorczuk DO, et al. Tricyclic antidepressants in red cells and plasma: correlation with impaired intraventricular conduction in acute overdose. Clinical Pharmacology and Therapeutics 54: 219–227, 1993

    PubMed  CAS  Google Scholar 

  • Anton Jr RF, Burch Jr EA. Amoxapine versus amitriptyline combined with Perphenazine in the treatment of psychotic depression. American Journal of Psychiatry 147: 1203–1208, 1990

    PubMed  Google Scholar 

  • Apseloff G, Wilner KD, von Deutsch AD, Henry EB, Tremaine LM, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. Journal of Clinical Pharmacology 32: 643–646, 1992

    PubMed  CAS  Google Scholar 

  • Apter JT, Woolfolk RL. Lithium augmentation of bupropion in refractory depression. Annals of Clinical Psychiatry 2: 7–10, 1990

    Google Scholar 

  • Aranow RB, Hudson JI, Pope HG, Grady RA, Laage TA, et al. Elevated antidepressant plasma levels after addition of fluoxetine. American Journal of Psychiatry 146: 911–913, 1989

    PubMed  CAS  Google Scholar 

  • Ayd Jr FJ. Epileptics, antidepressants and seizures. International Drug Therapy Newsletter 28: 1–4, 1993

    Google Scholar 

  • Baker GB, Coutts RT. Metabolism of monoamine oxidase inhibitors. Progress in Neuropsychopharmacology and Biological Psychiatry 13: 395–403, 1989

    CAS  Google Scholar 

  • Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine. Journal of Clinical Psychiatry 53: 212–213, 1992

    PubMed  CAS  Google Scholar 

  • Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. Journal of Clinical Psychiatry 54: 209–212, 1993

    PubMed  CAS  Google Scholar 

  • Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. British Medical Journal 303: 685–692, 1991

    PubMed  Google Scholar 

  • Beasley CM, Potvin JH, Masica DN, Wheadon DE, Dornseif BE, et al. Fluoxetine: no association with suicidality in obsessive-compulsive disorder. Journal of Affective Disorders 24: 1–10, 1992a

    PubMed  Google Scholar 

  • Beasley CM, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. Journal of Clinical Psychopharmacology 12: 328–333, 1992b

    PubMed  Google Scholar 

  • Bech P. A meta-analysis of the antidepressant properties of serotonin reuptake inhibitors. International Review of Psychiatry 2: 207–211, 1990

    Google Scholar 

  • Becker RE, Dufresne RL. Perceptual changes with bupropion, a novel antidepressant. American Journal of Psychiatry 139: 1200–1201, 1982

    PubMed  CAS  Google Scholar 

  • Bengtsson B-O, Lundmark J, Walinder J. No crossover reactions to Citalopram or paroxetine among patients hypersensitive to zimeldine. British Journal of Psychiatry 158: 853–855, 1991

    PubMed  CAS  Google Scholar 

  • Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 313–334, 1986

    PubMed  CAS  Google Scholar 

  • Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapeutics 51: 239–248, 1992

    PubMed  CAS  Google Scholar 

  • Berken GH, Weinstein DO, Stern WC. Weight gain: a side effect of tricyclic antidepressants. Journal of Affective Disorders 7: 133–138, 1984

    PubMed  CAS  Google Scholar 

  • Berlin I, Zimmer R, Cournot A, Payan C, Pedariosse AM, et al. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clinical Pharmacology and Therapeutics 46: 344–351, 1989

    PubMed  CAS  Google Scholar 

  • Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxaminetricyclic antidepressant interaction: an accidental finding. European Journal of Clinical Pharmacology 40: 119–120, 1991

    PubMed  CAS  Google Scholar 

  • Bieck PR, Antonin K. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. Journal of Clinical Psychopharmacology 8: 237–245, 1988

    PubMed  CAS  Google Scholar 

  • Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry 50: 44–50, 1993

    PubMed  CAS  Google Scholar 

  • Blackwell B. Treatment adherence. British Journal of Psychiatry 129: 513–531, 1976

    PubMed  CAS  Google Scholar 

  • Blackwell B. Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. Drugs 21: 201–219, 1981a

    PubMed  CAS  Google Scholar 

  • Blackwell B. Adverse effects of antidepressant drugs. Part 2: ’second generation’ anti-depressants and rational decision making in antidepressant therapy. Drugs 21: 273–282, 1981b

    PubMed  CAS  Google Scholar 

  • Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. Journal of Clinical Psychopharmacology 11: 55–59, 1991

    PubMed  CAS  Google Scholar 

  • Bougerai T, Uchida C, Gachoud J-P, Kohler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III): a French/Swiss double-blind trial. Psychopharmacology 106: 5102–5108, 1992

    Google Scholar 

  • Boyer WF, Blumhardt CL. The safety profile of paroxetine. Journal of Clinical Psychiatry 53(Suppl.): 61–66, 1992

    PubMed  Google Scholar 

  • Boyer WF, Feighner JR Side-effects of the selective serotonin re-uptake inhibitors. In Feighner & Boyer (Eds) Selective serotonin re-uptake inhibitors: the clinical use of Citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. Perspectives in Psychiatry, Vol. 1, pp. 133–152, John Wiley and Sons, Chichester, 1991

    Google Scholar 

  • Boyson SJ. Psychiatric effects of Selegiline. Archives of Neurology 48: 902, 1991

    PubMed  CAS  Google Scholar 

  • Brady KT, Lydiard RB, Kellner C. Tranylcypromine abuse. American Journal of Psychiatry 148: 1268–1269, 1991

    PubMed  CAS  Google Scholar 

  • Briggs NC, Jefferson JW, Koenecke FH. Tranylcypromine addiction: a case report and review. Journal of Clinical Psychiatry 51: 426–429, 1990

    PubMed  CAS  Google Scholar 

  • Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. Journal of Clinical Pharmacology 29: 529–532, 1989

    PubMed  CAS  Google Scholar 

  • Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment. British Journal of Psychiatry 151: 210–212, 1987

    PubMed  CAS  Google Scholar 

  • Burton SW. A review of fluvoxamine and its uses in depression. International Clinical Psychopharmacology 6(Suppl 3): 1–21, 1991

    PubMed  Google Scholar 

  • Caracci G, Decina P. Fluoxetine and prolonged seizure. Convulsive Therapy 7: 145–147, 1991

    PubMed  Google Scholar 

  • Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. British Medical Journal 295: 1021–1024, 1987

    PubMed  CAS  Google Scholar 

  • Chandler JD. Switching MAOIs. Journal of Clinical Psychopharmacology 7: 438, 1987

    Google Scholar 

  • Chaplin S. Bone marrow depression due to mianserin, Phenylbutazone, oxyphenbutazone, and chloramphenicol. Part I. Adverse Drug Reactions and Acute Poisoning Review 2: 97–136, 1986

    Google Scholar 

  • Choo V. Paroxetine and extrapyramidal reactions. Lancet 341: 624, 1993

    Google Scholar 

  • Chua TP, Vong SK. Hyponatraemia associated with paroxetine. British Medical Journal 306: 143, 1993

    PubMed  CAS  Google Scholar 

  • Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and anti-psychotics. Journal of Clinical Psychopharmacology 10: 48–50, 1990a

    PubMed  CAS  Google Scholar 

  • Ciraulo DA, Shader RI, Fluoxetine drug-drug interactions: II. Journal of Clinical Psychopharmacology 10: 213–217, 1990b

    PubMed  CAS  Google Scholar 

  • Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC. Paroxetine versus placebo: a double-blind comparison in depressed patients. Journal of Clinical Psychiatry 53: 434–438, 1992

    PubMed  CAS  Google Scholar 

  • Clary C, Schweizer E. Treatment of MAOI hypertensive crisis with sublingual nifedipine. Journal of Clinical Psychiatry 48: 249–250, 1987

    PubMed  CAS  Google Scholar 

  • Corona GL, Frattini P, Cucchi ML, Santagostino G, Schinelli S, et al. Viloxazine in depressed women: clinical response and cardiovascular effects. International Journal of Clinical Pharmacology, Therapy and Toxicology 25: 322–327, 1987

    CAS  Google Scholar 

  • Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 336: 785–787, 1990

    PubMed  CAS  Google Scholar 

  • Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology 34: 262–265, 1992

    PubMed  CAS  Google Scholar 

  • Cubeddu LX, Cloutier G, Gross K, Grippo R, Tanner L. Bupropion does not antagonize cardiovascular actions of Clonidine in normal subjects and spontaneously hypertensive rats. Clinical Pharmacology and Therapeutics 35: 576–584, 1984

    PubMed  CAS  Google Scholar 

  • Dager SR, Heritch AJ. A case of bupropion-associated delirium. Journal of Clinical Psychiatry 51: 307–308, 1990

    PubMed  CAS  Google Scholar 

  • Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure. American Journal of Psychiatry 148: 1601, 1991

    PubMed  CAS  Google Scholar 

  • Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90: 131–138, 1986

    Google Scholar 

  • Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 18: 289–299, 1990

    Google Scholar 

  • Davidson J. Seizures and bupropion: a review. Journal of Clinical Psychiatry 50: 256–261, 1989

    PubMed  CAS  Google Scholar 

  • Decastro RM. Reversal of MAOI-induced anorgasmia with cyproheptadine. American Journal of Psychiatry 142: 783, 1985

    PubMed  CAS  Google Scholar 

  • de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 43(Suppl 2): 40–47, 1992

    PubMed  Google Scholar 

  • DeMaso D, Hunter T. Combining fluoxetine with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry 29: 151, 1990

    PubMed  CAS  Google Scholar 

  • DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry 53(Suppl.): 13–20, 1992

    PubMed  Google Scholar 

  • DeVane CL, Laizure SC, Stewart JT, Kolts BE, Ryerson EG, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. Journal of Clinical Psychopharmacology 10: 328–332, 1990

    PubMed  CAS  Google Scholar 

  • DeWilde J, Spiers R, Mertens C, Bartholome F, Schotte G, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatrica Scandinavica 87: 141–145, 1993

    CAS  Google Scholar 

  • Doogan DP, Caillard V. Sertraline in the prevention of depression. British Journal of Psychiatry 160: 217–222, 1992

    PubMed  CAS  Google Scholar 

  • Dorman T. Toxicity of tricyclic antidepressants: are there important differences? Journal of International Medical Research 13: 77–83, 1985

    PubMed  CAS  Google Scholar 

  • Downs JM, Downs AD, Rosenthal TL, Deal N, Akiskal HS. Increased plasma tricyclic anti-depressant concentrations in two patients concurrently treated with fluoxetine. Journal of Clinical Psychiatry 50: 226–227, 1989

    PubMed  CAS  Google Scholar 

  • Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, et al. A comparison of paroxetine, Imipramine and placebo in depressed outpatients. British Journal of Psychiatry 159: 394–398, 1991

    PubMed  CAS  Google Scholar 

  • Dunner DL, Cohn JB, Walshe III T, Cohn CK, Feighner JP, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. Journal of Clinical Psychiatry 53(Suppl.): 57–60, 1992

    PubMed  Google Scholar 

  • Edwards JC, Glenn-Bott M. Does viloxazine have epileptogenic properties? Journal of Neurology, Neurosurgery and Psychiatry 47: 960–964, 1984

    CAS  Google Scholar 

  • Eisenberg L. Treating depression and anxiety in primary care: closing the gap between knowledge and practice. New England Journal of Medicine 326: 1080–1084, 1992

    PubMed  CAS  Google Scholar 

  • Evans M, Marwick P. Fluvoxamine and lithium: an unusual interaction. British Journal of Psychiatry 156: 286, 1990

    PubMed  CAS  Google Scholar 

  • Extein IL. Recent fluoxetine treatment and complications of tricyclic therapy. American Journal of Psychiatry 148: 1601–1602, 1991

    PubMed  CAS  Google Scholar 

  • Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. Journal of Clinical Psychiatry 52(Suppl.): 62–67, 1991

    PubMed  Google Scholar 

  • Fallon B, Foote B, Walsh T, Roose SP. ’spontaneous’ hypertensive episodes with monoamine oxidase inhibitors. Journal of Clinical Psychiatry 49: 163–165, 1988

    PubMed  CAS  Google Scholar 

  • Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? Journal of Clinical Psychiatry 52: 108–111, 1991

    PubMed  CAS  Google Scholar 

  • Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. Journal of Clinical Psychiatry 52: 163–164, 1991

    PubMed  CAS  Google Scholar 

  • Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. Journal of Clinical Psychiatry 51: 222–225, 1990

    PubMed  CAS  Google Scholar 

  • Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. Journal of Clinical Psychiatry 52: 329–335, 1991

    PubMed  CAS  Google Scholar 

  • Feighner J, Hendrickson G, Miller L, Stern W. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. Journal of Clinical Psychopharmacology 6: 27–32, 1986

    PubMed  CAS  Google Scholar 

  • Fernstrom MD, Krowinski RL, Kupfer DJ. Chronic imipramine treatment and weight gain. Psychiatry Research 17: 269–273, 1986

    PubMed  CAS  Google Scholar 

  • Figiel GS, Jarvis MR. Electroconvulsive therapy in a depressed patient receiving bupropion. Journal of Clinical Psychopharmacology 10: 376, 1990

    PubMed  CAS  Google Scholar 

  • Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatrica Scandinavica 84: 583–584, 1991

    PubMed  CAS  Google Scholar 

  • Gardner EA, Johnston JA. Bupropion — an antidepressant without sexual pathophysiological action. Journal of Clinical Psychopharmacology 5: 24–29, 1985

    PubMed  CAS  Google Scholar 

  • Gelenberg AJ. Switching MAOIs: part 3. Biological Therapies in Psychiatry 10: 7, 1987

    Google Scholar 

  • George MS, Trimble MR. A fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourettes’s syndrome and obsessive compulsive disorder. Journal of Clinical Psychiatry 53: 379, 1992

    PubMed  CAS  Google Scholar 

  • Gernaat HBPE, Van De Woude J, Touw DJ. Fluoxetine and Parkinsonism in patients taking carbamazepine. American Journal of Psychiatry 148: 1604–1605, 1991

    PubMed  CAS  Google Scholar 

  • Gifford RW. Management of hypertensive crises. Journal of the American Medical Association 266: 829–835, 1991

    PubMed  Google Scholar 

  • Gill K, Filion Y, Amit A. A further examination of the effects of sertraline on voluntary ethanol consumption. Alcohol 5: 355–358, 1988

    PubMed  CAS  Google Scholar 

  • Glassman AH, Roose SP, Bigger Jr JT. The safety of tricyclic antidepressants in cardiac patients: risk-benefit considered. Journal of the American Medical Association 269: 2673–2675, 1993

    PubMed  CAS  Google Scholar 

  • Glassman AH, Roose SP, Giardina EGV, Bigger Jr JT. Cardiovascular effects of tricyclic antidepressants. In Meltzer HY (Ed.) Psychopharmacolgy: the third generation of progress, pp. 1437–1442, Raven Press, New York, 1987

    Google Scholar 

  • Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinsons’s disease. Neurology 34: 1092–1094, 1984

    PubMed  CAS  Google Scholar 

  • Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. American Journal of Psychiatry 148: 790–792, 1991

    PubMed  CAS  Google Scholar 

  • Goff DC, Renshaw PF, Savid-Segal O, Dreyfuss DA, Amico ET, et al. A placebo-controlled trial of Selegiline (1-deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry 33: 700–706, 1993

    PubMed  CAS  Google Scholar 

  • Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Journal of Clinical Psychiatry 52: 261–262, 1991

    PubMed  CAS  Google Scholar 

  • Golden RN, James SP, Sherer MA, Rudorfer MV, Sack DA, et al. Psychoses associated with bupropion treatment. American Journal of Psychiatry 142: 1459–1462, 1985

    PubMed  CAS  Google Scholar 

  • Golden RN, DeVane CL, Laizure SC, Rudorfer MV, Sherer MA, et al. Bupropion in depression: II. The role of metabolites in clinical outcome. Archives of General Psychiatry 45: 145–149, 1988a

    PubMed  CAS  Google Scholar 

  • Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression: I. Biochemical effects and clinical response. Archives of General Psychiatry 45: 139–143, 1988b

    PubMed  CAS  Google Scholar 

  • Goode DJ, Manning AA. Comparison of bupropion alone and with haloperidol in schizoaffective disorder, depressed type. Journal of Clinical Psychiatry 44: 253–255, 1983

    PubMed  CAS  Google Scholar 

  • Goodman W, Kozak M, Liebowitz M, White K. Fluvoxamine in the treatment of obsessive-compulsive disorder: a multicenter doubleblind placebo-controlled study in outpatients. Presented at the New Clinical Drug Evaluation Unit 32nd Annual Meeting, Boca Raton, Florida, USA, May 1992

  • Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacology Bulletin 27: 503–512, 1991

    PubMed  CAS  Google Scholar 

  • Goodwin FK, Jamison KR. Manic-depressive illness. Oxford University Press, New York, 1990

    Google Scholar 

  • Graham PM. Combined mianserin and tranylcypromine. British Journal of Psychiatry 153: 415–416, 1988

    PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapeutics 52: 479–486, 1992

    PubMed  CAS  Google Scholar 

  • Griffith JD, Carranza J, Griffith C, Miller LL. Bupropion: clinical assay for amphetamine-like abuse potential. Journal of Clinical Psychiatry 44 (Section 2): 206–208, 1983

    PubMed  CAS  Google Scholar 

  • Guelfi JD, Payan C, Fermanian J, Pedarriosse A-M, Manfredi R. Moclobemide versus clomipramine in endogenous depression: a double-blind randomised clinical trial. British Journal of Psychiatry 160: 519–524, 1992

    PubMed  CAS  Google Scholar 

  • Guthrie SK. Sertraline: a new specific serotonin reuptake blocker. Annals of Pharmacotherapy 25: 952–961, 1991

    PubMed  CAS  Google Scholar 

  • Gutierrez-Esteinou R, Pope Jr HG. Does fluoxetine prolong electrically induced seizures? Convulsive Therapy 5: 344–348, 1989

    PubMed  Google Scholar 

  • Hadley A, Cason MR Mania resulting from lithium-fluoxetine combination. American Journal of Psychiatry 52: 217–220, 1991

    Google Scholar 

  • Halbreich U, Rojansky N, Bakhal Y, Wang K. Menstrual irregularities associated with bupropion treatment. Journal of Clinical Psychiatry 52: 15–16, 1991

    PubMed  CAS  Google Scholar 

  • Hamilton MJ, Bush MS, Peck AW. The effect of bupropion, a new antidepressant drug, and alcohol and their interaction in man. European Journal of Clinical Pharmacology 27: 75–80, 1984

    PubMed  CAS  Google Scholar 

  • Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. Journal of Clinical Pychiatry 53: 401–406, 1992

    CAS  Google Scholar 

  • Harmant J, van Rijckevorsel-Harmant K, de Barsy, T, Hendrickx B. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet 336: 386, 1990

    PubMed  CAS  Google Scholar 

  • Harrison W, McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. Journal of Clinical Psychiatry 50: 64–65, 1989

    PubMed  CAS  Google Scholar 

  • Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. Journal of Clinical Psychiatry 51: 450–455, 1990

    PubMed  CAS  Google Scholar 

  • Henry JA. The safety of antidepressants. British Journal of Psychiatry 160: 439–441, 1992

    PubMed  CAS  Google Scholar 

  • Henry JA, Martin AJ. The risk-benefit assessment of antidepressant drugs. Medical Toxicology 2: 445–462, 1987

    PubMed  CAS  Google Scholar 

  • Hetzel W. Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacology 106(Suppl.): 127–129, 1992

    Google Scholar 

  • Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clincal Psychopharmacology 10: 343–345, 1990

    CAS  Google Scholar 

  • Horne RL, Ferguson JM, Pope Jr HG, Hudson JI, Lineberry CG, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. Journal of Clinical Psychiatry 49: 262–266, 1988

    PubMed  CAS  Google Scholar 

  • Inman WH. Blood disorders and suicide in patients taking mianserin or amitriptyline. Lancet 2: 90–92, 1988

    PubMed  CAS  Google Scholar 

  • Jacobsen FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. Journal of Clinical Psychiatry 51: 298–302, 1990

    PubMed  CAS  Google Scholar 

  • Jacobsen FM. Possible augmentation of antidepressant response by buspirone. Journal of Clinical Psychiatry 52: 217–220, 1991

    PubMed  CAS  Google Scholar 

  • Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Journal of Clinical Psychiatry 53: 119–122, 1992

    PubMed  CAS  Google Scholar 

  • Jansen Steur ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211–213, 1993

    Google Scholar 

  • Jarvis MR. Clinical pharmacokinetics of tricyclic antidepressant overdose. Psychopharmacology Bulletin 27: 541–550, 1991

    PubMed  CAS  Google Scholar 

  • Jefferson JW. Is tranylcypromine really metabolized to amphetamine? Journal of Clinical Psychiatry 53: 450–451, 1992

    PubMed  CAS  Google Scholar 

  • Jeffries J, Bezchlibnyk-Butler K, Remington G. Amenorrhea and galactorrhea associated wth fluvoxamine in a loxapine-treated patient. Journal of Clinical Psychopharmacology 12: 296–297, 1992

    PubMed  CAS  Google Scholar 

  • Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology 52: 13–14, 1991

    CAS  Google Scholar 

  • Johnson DAW. Depression: treatment compliance in general practice. Acta Psychiatrica Scandivanica 63(Suppl. 290): 447–453, 1981

    Google Scholar 

  • Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. Journal of the American Medical Association 267: 1478–1483, 1992

    PubMed  CAS  Google Scholar 

  • Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, et al. A 102-center prospective study of seizure in association with bupropion. Journal of Clinical Psychiatry 52: 450–456, 1991

    PubMed  CAS  Google Scholar 

  • Kahn DA. Possible toxic interaction between cyproheptadine and phenelzine. American Journal of Psychiatry 144: 1242–1243, 1987

    PubMed  CAS  Google Scholar 

  • Kahn DA, Silver JM, Opler LA. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology 9: 198–202, 1989

    PubMed  CAS  Google Scholar 

  • Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. Journal of the American Medical Association 268: 3441–3445, 1992

    PubMed  CAS  Google Scholar 

  • Kasper S, Fuger J, Moller H-J. Comparative efficacy of antidepressants. Drugs 43(Suppl. 2): 11–23, 1992

    PubMed  Google Scholar 

  • Keck PE, Carter WP, Nierenberg AA, Cooper TB, Potter WZ, et al. Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. Journal of Clinical Psychiatry 52: 250–254, 1991a

    PubMed  Google Scholar 

  • Keck PE, Hudson JI, Dorsey CM, Campbell PI. Effect of fluoxetine on sleep. Biological Psychiatry 29: 618–619, 1991b

    PubMed  Google Scholar 

  • Keck PE, Pope HG, Nierenberg AA. Autoinduction of hypertensive reactions by tranylcypromine? Journal of Clinical Psychopharmacology 9: 48–51, 1989

    PubMed  Google Scholar 

  • Kellner CH, Nixon DW, Bernstein HJ. ECT-drug interactions: a review. Psychopharmacology Bulletin 27: 595–609, 1991

    PubMed  CAS  Google Scholar 

  • Kerihuel JC, Dreyfus JF. Meta-analyses of the efficacy and tolerability of the tricyclic antidepressant lofepramine. Journal of International Medical Research 19: 183–201, 1991

    PubMed  CAS  Google Scholar 

  • Kerr JS, Sherwood N, Hindmarch I. The comparative psychopharmacology of 5HT reuptake inhibitors. Human Psychopharmacology 6: 313–317, 1991

    CAS  Google Scholar 

  • Kincaid RL, McMullin MM, Crookham SB, Rieders F. Report of a fluoxetine fatality. Journal of Analytical Toxicology 14: 327–329, 1990

    PubMed  CAS  Google Scholar 

  • Korn A, Eichler HG, Fischbach R, Gasic S. Moclobemide, a new reversible MAO inhibitor: interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology 88: 153–157, 1986

    PubMed  CAS  Google Scholar 

  • Krijzer F, Snelder M, Bradford D. Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology 12: 249–254, 1984

    PubMed  CAS  Google Scholar 

  • Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski VJ, et al. Fluvoxamine versus desipramine: comparative Polysomnographic effects. Biological Psychiatry 29: 23–40, 1991

    PubMed  CAS  Google Scholar 

  • Lack SJ, Baldwin DS, Montgomery SA. Lofepramine, desipramine and abnormal tests of liver function: a case report. International Clinical Psychopharmacology 5: 185–190, 1990

    PubMed  CAS  Google Scholar 

  • Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, et al. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. Journal of Clinical Psychiatry 54: 224–228, 1993

    PubMed  CAS  Google Scholar 

  • Lamb RJ, Griffiths RR. Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine, and imipramine. Psychopharmacology 102: 183–190, 1990

    PubMed  CAS  Google Scholar 

  • Lambert C, Park BK, Kitteringham NR. Activation of mianserin and its metabolites by human liver microsomes. Biochemical Pharmacology 38: 2853–2858, 1989

    PubMed  CAS  Google Scholar 

  • Lancaster SG, Gonzalez JP. Lofepramine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 37: 123–140, 1989a

    PubMed  CAS  Google Scholar 

  • Lancaster SG, Gonzalez JP. Dothiepin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 38: 123–147, 1989b

    PubMed  CAS  Google Scholar 

  • Lavin MR, Mendelowitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biological Psychiatry 34: 146–151, 1993

    PubMed  CAS  Google Scholar 

  • Lawrin MO, Naranjo CA, Sellers EM. Identification and testing of new drugs for modulating alcohol consumption. Psychopharmacology Bulletin 22: 1020–1025, 1986

    CAS  Google Scholar 

  • Lebegue B. Survivable fluvoxamine overdose. American Journal of Psychiatry 147: 1689, 1990

    PubMed  CAS  Google Scholar 

  • Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics 43: 412–419, 1988

    PubMed  CAS  Google Scholar 

  • Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 43(Suppl. 2): 3–10, 1992

    PubMed  CAS  Google Scholar 

  • Leznoff A, Binkley KE, Joffe RT, Levitt A, Richter MA. Adverse cutaneous reactions associated with fluoxetine: strategy for reintroduction of this drug in selected patients. Journal of Clinical Psychopharmacology 12: 355–357, 1992

    PubMed  CAS  Google Scholar 

  • Liberzon I, Dequardo JR, Silk KR. Bupropion and delirium. American Journal of Psychiatry 147: 1689–1690, 1990

    PubMed  CAS  Google Scholar 

  • Lineberry CG, Johnston JA, Raymond RN, Samara B, Feighner JP, et al. A fixed-dose (300mg) efficacy study of bupropion and placebo in depressed outpatients. Journal of Clinical Psychiatry 51: 194–199, 1990

    PubMed  CAS  Google Scholar 

  • Linnoila M, Stapleton JM, George DT, Lane E, Eckardt MJ. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Journal of Clinical Psychopharmacology 13: 175–180, 1993

    PubMed  CAS  Google Scholar 

  • Lipinski Jr JF, Mallya G, Zimmerman P, Pope Jr HG. Fluoxetine-induced akathisia: clinical and theoretical implications. Journal of Clinical Psychiatry 50: 339–342, 1989

    PubMed  Google Scholar 

  • Lippman SB, Nash K. Monoamine oxidase inhibitor update: potential adverse food and drug interactions. Drug Safety 5: 195–204, 1990

    PubMed  CAS  Google Scholar 

  • Lock JD, Gwirtsman HE, Targ EF. Possible adverse drug interactions between fluoxetine and other psychotropics. Journal of Clinical Psychopharmacology 10: 383–384, 1990

    PubMed  CAS  Google Scholar 

  • Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacology Bulletin 27: 493–502, 1991

    PubMed  CAS  Google Scholar 

  • Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, et al. A controlled study of the antidepressant efficacy and side effects of (—)-deprenyl. Archives of General Psychiatry 46: 45–50, 1989

    PubMed  CAS  Google Scholar 

  • Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Archives of General Psychiatry 48: 1027–1033, 1991

    PubMed  CAS  Google Scholar 

  • Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge eaters. American Journal of Psychiatry 147: 876–881, 1990

    PubMed  CAS  Google Scholar 

  • Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. American Journal of Psychiatry 147: 798–800, 1990

    PubMed  CAS  Google Scholar 

  • McClelland GR, Raptopoulos P. Psychomotor effects of paroxetine and amitriptyline, alone and in combination with ethanol. British Journal of Clinical Pharmacology 19: 578P, 1985

    Google Scholar 

  • McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cypro-heptadine in two patients. Journal of Clinical Psychiatry 51: 383–384, 1990

    PubMed  CAS  Google Scholar 

  • McGrath PJ, Stewart JW, Quitkin FM. A possible L-deprenyl induced hypertensive reaction. Journal of Clinical Psychopharmacology 9: 310–311, 1989

    PubMed  CAS  Google Scholar 

  • Mendlewicz J. Efficacy of fluvoxamine in severe depression. Drugs 43(Suppl. 2): 32–39, 1992

    PubMed  Google Scholar 

  • Metz A. Interaction between fluoxetine and buspirone. Canadian Journal of Psychiatry 35: 722–723, 1990

    CAS  Google Scholar 

  • Metz A, Shader RL. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. International Clinical Psychopharmacology 5: 191–194, 1990

    PubMed  CAS  Google Scholar 

  • Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: 450–477, 1991

    PubMed  CAS  Google Scholar 

  • Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. Journal of Clinical Neurophysiology 7: 93–118, 1990

    PubMed  CAS  Google Scholar 

  • Montgomery SA. Suicide and antidepressants. Drugs 43(Suppl. 2): 24–31, 1992

    PubMed  Google Scholar 

  • Moon CAL, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. British Journal of Clinical Practice 45: 259–262, 1991

    PubMed  CAS  Google Scholar 

  • Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatrica Scandinavica 78: 384–390, 1988

    PubMed  CAS  Google Scholar 

  • Naranjo CA, Bremner KE, Lanctot KL. Short- and long-term effects of Citalopram combined with a brief psychosocial intervention for alcoholism. Clinical Pharmacology and Therapeutics 51: 168, 1992

    Google Scholar 

  • Nielsen BM, Behnke K, Arup P, Christiansen PE, Geisler A, et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatrica Scandinavica 87: 269–272, 1993

    PubMed  CAS  Google Scholar 

  • Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Archives of General Psychiatry 48: 303–307, 1991

    PubMed  CAS  Google Scholar 

  • Nierenberg AA, Cole JO. Antidepressant adverse drug reactions. Journal of Clinical Psychiatry 52(Suppl.): 40–47, 1991

    PubMed  Google Scholar 

  • Nierenberg AA, Keck Jr PE. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. Journal of Clinical Psychopharmacology 9: 42–45, 1989

    PubMed  CAS  Google Scholar 

  • Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clinical Pharmacology and Therapeutics 53: 84–88, 1993

    PubMed  CAS  Google Scholar 

  • Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. American Journal of Psychiatry 146: 1515, 1989

    PubMed  CAS  Google Scholar 

  • Ohrberg S, Christiansen PE, Severin B, Calberg H, Nilakantan B, et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatrica Scandinavica 86: 437–444, 1992

    PubMed  CAS  Google Scholar 

  • Peck AW, Hamilton M. Psychopharmacology of bupropion in normal volunteers. Journal of Clinical Psychiatry 44 (Section 2): 202–205, 1983

    PubMed  CAS  Google Scholar 

  • Pickar D, Cohen RM, Jimerson DC, Lake CR, Murphy DL. Tyramine infusions and selective monoamine oxidase inhibitor treatment and plasma MHPG reduction. Psychopharmacology 74: 8–12, 1981

    PubMed  CAS  Google Scholar 

  • Pirmohamed M, Kitteringham NR, Park BK. Idiosyncratic reactions to antidepressants: a review of the possible mechanisms and predisposing factors. Pharmacology and Therapeutics 53: 105–125, 1992

    PubMed  CAS  Google Scholar 

  • Pisani F, Fazio A, Spina E, Artesi C, Pisani B, et al. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology 90: 295–298, 1986

    PubMed  CAS  Google Scholar 

  • Posner J, Hye A, Dean K, Peck AW, Whiteman P. Alcohol and bupropion pharmacokinetics in healthy male volunteers. European Journal of Clinical Pharmacology 26: 627–630, 1984

    PubMed  CAS  Google Scholar 

  • Posner J, Hye A, Dean K, Peck AW, Whiteman PD. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. European Journal of Clinical Pharmacology 29: 97–103, 1985

    PubMed  CAS  Google Scholar 

  • Potter WZ, Rudorfer MV, Manji HK. The pharmacologic treatment of depression. New England Journal of Medicine 325: 633–642, 1991

    PubMed  CAS  Google Scholar 

  • Power AC, Cowen PJ. Fluoxetine and suicidal behaviour: some clinical and theoretical aspects of a controversy. British Journal of Psychiatry 161: 735–741, 1992

    PubMed  CAS  Google Scholar 

  • Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. American Journal of Psychiatry 147: 532, 1990

    PubMed  CAS  Google Scholar 

  • Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry 52 (Suppl.): 23–33, 1991

    PubMed  Google Scholar 

  • Preskorn SH, Alderman J, Harris S, Chung M. Desipramine levels after sertraline or fluoxetine. Presented at the Annual Meeting of the American Psychiatric Association (Abstract NR578), Washington, D.C., May 1992

  • Provost J-C, Funck-Brentano C, Rovei V, Ds’Estanque J, Ego D, et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clinical Pharmacology and Therapeutics 52: 384–393, 1992

    PubMed  CAS  Google Scholar 

  • Rahman MK, Akhtar MJ, Savla NC, Sharma RR, Kellett JM, et al. A double-blind randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. British Journal of Clinical Practice 45: 255–258, 1991

    PubMed  CAS  Google Scholar 

  • Ray WA. Psychotropic drugs and injuries among the elderly: a review. Journal of Clinical Psychopharmacology 12: 386–396, 1992

    PubMed  CAS  Google Scholar 

  • Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Journal of Clinical Psychiatry 51(Suppl. B): 18–27, 1990

    PubMed  Google Scholar 

  • Remick RA, Jewesson P, Ford RWJ. Monoamine oxidase inhibitors in general anesthesia: a reevaluation. Convulsive Therapy 3: 196–203, 1987

    PubMed  Google Scholar 

  • Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmacology and Experimental Therapeutics 230: 94–102, 1984

    PubMed  CAS  Google Scholar 

  • Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. American Journal of Psychiatry 148: 512–516, 1991a

    PubMed  CAS  Google Scholar 

  • Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, et al. Is doxepin a safer tricyclic for the heart? Journal of Clinical Psychiatry 52: 338–341, 1991b

    PubMed  CAS  Google Scholar 

  • Roose SP, Glassman AH, Giardina EGV, Johnson LL, Walsh BT, et al. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. Journal of Clinical Psychopharmacology 7: 247–251, 1987

    PubMed  CAS  Google Scholar 

  • Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. Journal of Clinical Psychiatry 54: 289–299, 1993

    PubMed  CAS  Google Scholar 

  • Rosenstein DL, Takeshita J, Nelson JC. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose. American Journal of Psychiatry 148: 807, 1991

    PubMed  CAS  Google Scholar 

  • Ross RJ, Zavadil AP, Calil HM, Linnoila M, Kitanaka I, et al. The effects of desmethyl-imipramine on norepinephrine, pulse and blood pressure in volunteers. Clinical Pharmacology and Therapeutics 33: 429–437, 1983

    PubMed  CAS  Google Scholar 

  • Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Journal of Clinical Psychiatry 52: 491–493, 1991

    PubMed  CAS  Google Scholar 

  • Rouillon F, Serrurier D, Miller HD, Gerard M-J. Prophylactic efficacy of maprotiline on unipolar depression relapse. Journal of Clinical Psychiatry 52: 423–431, 1991

    PubMed  CAS  Google Scholar 

  • Rudorfer MV. Parkinsons’s caveat, Newsweek, p. 14, December 25, 1989

  • Rudorfer MV. Pharmacokinetics of psychotropic drugs in special populations. Journal of Clinical Psychiatry 54 (Suppl.): 50–54, 1993

    PubMed  Google Scholar 

  • Rudorfer MV, Golden RN, Potter WZ. Second generation antidepressants. In Lake CR (Ed.) Clinical psychopharmacology. Psychiatric Clinics of North America 7: 519–534, 1984

  • Rudorfer MV, Manji HK, Potter WZ. Bupropion, ECT, and dopaminergic overdrive. American Journal of Psychiatry 148: 1101–1102, 1991

    PubMed  CAS  Google Scholar 

  • Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In Meltzer HY (Ed.) Psychopharmacology: the third generation of progress, pp. 1353–1363, Raven Press, New York, 1987

    Google Scholar 

  • Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs 37: 713–738, 1989

    PubMed  CAS  Google Scholar 

  • Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. Journal of Clinical Psychiatry 43: 457–460, 1982

    PubMed  CAS  Google Scholar 

  • Rudorfer MV, Young RC. Desipramine: cardiovascular effects and plasma levels. American Journal of Psychiatry 137: 984–986, 1980a

    PubMed  CAS  Google Scholar 

  • Rudorfer MV, Young RC. Anticholinergic effects and plasma desipramine levels. Clinical Pharmacology and Therapeutics 28: 703–706, 1980b

    PubMed  CAS  Google Scholar 

  • Sacristan JA, Iglesias C, Arellano F, Lequerica J. Absence seizures induced by lithium: possible interaction with fluoxetine. American Journal of Psychiatry 148: 146–147, 1991

    PubMed  CAS  Google Scholar 

  • Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. American Journal of Psychiatry 146: 278, 1989

    PubMed  CAS  Google Scholar 

  • Segraves RT. Overview of sexual dysfunction complicating the treatment of depression. Journal of Clinical Psychiatry Monograph 19: 4–10, 1992

    Google Scholar 

  • Sheehan D, Dunbar GC, Fuell DL. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacology Bulletin 28: 139–143, 1992

    PubMed  CAS  Google Scholar 

  • Shoaf SE, Linnoila M. Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacology Bulletin 27: 577–594, 1991

    PubMed  CAS  Google Scholar 

  • Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology 9: 397–402, 1989

    PubMed  CAS  Google Scholar 

  • Simpson GM, Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clinical Pharmacology and Therapeutics 52: 286–291, 1992

    PubMed  CAS  Google Scholar 

  • Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, et al. The selective serotonin reuptake inhibitor Citalopram relieves the symptoms of diabetic neuropathy. Clinical Pharmacology and Therapeutics 52: 547–552, 1992

    PubMed  CAS  Google Scholar 

  • Song F, Freemantle N, Sheldon TA, House A, Watson P, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal 306: 683–687, 1993

    PubMed  CAS  Google Scholar 

  • Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 6: 460–462, 1991

    PubMed  CAS  Google Scholar 

  • Spigset O, Mjörndal T, Lövheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. British Medical Journal 306: 248, 1993

    PubMed  CAS  Google Scholar 

  • Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. American Journal of Psychiatry 148: 683, 1991

    PubMed  CAS  Google Scholar 

  • Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 2: 850–851, 1988

    PubMed  CAS  Google Scholar 

  • Sternbach H. The serotonin syndrome. American Journal of Psychiatry 148: 705–713, 1991

    PubMed  CAS  Google Scholar 

  • Suchowersky O, deVries JD. Interaction of fluoxetine and Selegiline. Canadian Journal of Psychiatry 35: 571–572, 1990

    CAS  Google Scholar 

  • Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, et al. Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86: 432–437, 1985

    PubMed  CAS  Google Scholar 

  • Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry 147: 207–210, 1990

    PubMed  CAS  Google Scholar 

  • Thomas JM, Rubin EH. Case report of a toxic reaction from a combination of tryptophan and phenelzine. American Journal of Psychiatry 141: 281–283, 1984

    PubMed  CAS  Google Scholar 

  • Thompson JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. Journal of Clinical Psychiatry 51: 430–433, 1990

    PubMed  Google Scholar 

  • Tingelstad J. The cardiotoxicity of the tricyclics. Journal of the American Academy of Child and Adolescent Psychiatry 30: 845–846, 1991

    PubMed  CAS  Google Scholar 

  • Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. Journal of Clinical Psychiatry 54: 27–32, 1993

    PubMed  Google Scholar 

  • van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics 24: 203–220, 1993

    PubMed  Google Scholar 

  • van Putten T, Shaffer L. Delirium associated with bupropion. Journal of Clinical Psychopharmacology 10: 234, 1990

    PubMed  Google Scholar 

  • Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose. British Journal of Psychiatry 158: 856–857, 1991

    PubMed  CAS  Google Scholar 

  • Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. American Journal of Psychiatry 145: 1478, 1988

    PubMed  CAS  Google Scholar 

  • Versiani M, Nardi AE, Figueira ILV, Stabl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatrica Scandinavica 82(Suppl. 360): 24–28, 1990

    Google Scholar 

  • Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. British Journal of Psychiatry 161: 353–360, 1992

    PubMed  CAS  Google Scholar 

  • Vinar O, Klein DF, Potter WZ, Gause EM. A survey of psychotropic medications not available in the United States. Neuropsychopharmacology 5: 201–217, 1991

    PubMed  CAS  Google Scholar 

  • Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H. Review of fluvoxamine safety database. Drugs 43(Suppl. 2): 48–54, 1992

    PubMed  Google Scholar 

  • Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. Journal of Clinical Psychiatry 50: 447–449, 1989

    PubMed  CAS  Google Scholar 

  • Weingartner H, Rudorfer MV, Buchsbaum MS, Linnoila M. Effects of serotonin on memory impairments produced by ethanol. Science 221: 472–474, 1983

    PubMed  CAS  Google Scholar 

  • Wenger TL, Cohn JB, Bustrack J. Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients. Journal of Clinical Psychiatry 44 (Section 2): 174–175, 1983

    PubMed  CAS  Google Scholar 

  • Westermeyer J. Fluoxetine-induced tricyclic toxicity: extent and duration. Journal of Clinical Pharmacology 31: 388–392, 1991

    PubMed  CAS  Google Scholar 

  • Wilens TE, Biederman J, Baldessarini RJ, McDermott SP, Puopolo PR. Fluoxetine inhibits desipramine metabolism. Archives of General Psychiatry 49: 752, 1992

    PubMed  CAS  Google Scholar 

  • Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D. Fluoxetine, akathisia, and suicidality: is there a causal connection? Archives of General Psychiatry 49: 580–581, 1992

    PubMed  CAS  Google Scholar 

  • Zajecka J, Fawcett J. Susceptibility to spontaneous MAOI hypertensive episodes. Journal of Clinical Psychiatry 52: 513–514, 1991

    PubMed  CAS  Google Scholar 

  • Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasmic dysfunction. Journal of Clinical Psychiatry 52: 66–68, 1991

    PubMed  CAS  Google Scholar 

  • Zis AP. Acute administration of fluoxetine and the duration of electrically induced seizures. Convulsive Therapy 8: 38–39, 1992

    PubMed  Google Scholar 

  • Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and Selegiline. Lancet 337: 246, 1991

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section on Clinical Pharmacology, Experimental Therapeutics Branch, Intramural Research Program, National Institute of Mental Health, Building 10, Room 2D46, 9000 Rockville Pike, Bethesda, Maryland, 20892, USA

    Matthew V. Rudorfer, Husseini K. Manji &  William Z. Potter

  2. Clinical Treatment Research Branch, Division of Clinical and Treatment Research, National Institutes of Health, National Institute of Mental Health, Bethesda, Maryland, USA

    Matthew V. Rudorfer, Husseini K. Manji &  William Z. Potter

Authors
  1. Matthew V. Rudorfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Husseini K. Manji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William Z. Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rudorfer, M.V., Manji, H.K. & Potter, W.Z. Comparative Tolerability Profiles of the Newer versus Older Antidepressants. Drug-Safety 10, 18–46 (1994). https://doi.org/10.2165/00002018-199410010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199410010-00003

Keywords

Search

Navigation